Xebec Adsorption has “massive” potential, M Partners says

Investors looking to get in early on a name that could become a leader in the renewable natural gas space should take a close look at Xebec Adsorption (Xebec Adsorption Stock Quote, Chart TSXV:XBC), says M Partners analyst Andrew Hood.

In a research report to clients today, Hood initiated coverage of Xebec with a “Buy” rating and a one-year price target of $2.20, implying a return of 71 per cent at the time of publication.

Hood says that after several years of false starts, Xebec now has clear momentum.

“Xebec is a leading cleantech provider in the early stages for renewable natural gas,” the analyst notes. “XBC systems provide the most reliable, low-cost performance for upgrading biogas to pipelinequality RNG. With the premium cost of RNG acting as a barrier to acceptance by utility regulators, lower-cost systems enjoy a competitive advantage. Xebec is gaining traction, increasing order backlog from $16.7M to $71.4M over the past year.”

The says Xebec is essentially facilitating mandated demand.

“Government support for GHG reduction globally supports investments in RNG infrastructure, with many policies mandating minimum biomethane content,” he adds. “RNG presents the simplest, most reliable solution, with 95% reduction in carbon emissions vs. fossil natural gas, and the flexibility to inject directly into the existing grid. For countries to meet emissions reduction goals, they must invest over the next few years. The market for equipment sales is over $6B in Xebec’s target markets (France, Italy, United States and Canada) for roughly 1,700 potential projects. Investments are already underway, with a $51M order from Sapio in Italy and a $5.5M contract from Enbridge in Toronto over the past year. In the U.S., the opportunity lies in 120-160 landfill sites, at $15-25M for a biogas upgrading contract.”

Hood thinks Xebec will post EBITDA of $1.5-million on revenue of $24.0-million in fiscal 2018. He expects those numbers will improve to EBITDA of $3.8-million on a topline of $45.0-million the following year.

The analyst concludes that Xebec has “massive potential” extending far beyond his admittedly short-term target.

“For the purposes of our target price, our valuation is based on a short-term forecast – longer term we believe Xebec will only continue to generate value for shareholders,” Hood adds. “Since our forecast is focused on the short term, we do not factor in any contributions from the BOO or Power-to-Gas segments, which could ultimately contribute half of Xebec’s revenues in the long-term. We also note that even our short-term forecast would need to be revised in the event that Xebec signs even one landfill order in the U.S. A single order could add $15-25M in revenues and $3.7-7.5M in EBITDA on top of our forecast. Management has guided for $40M in revenues in 2019 as the conservative scenario, and they believe they are likely close to $50M, or $75M with a landfill order. EPS guidance is $0.05 to $0.07 for the year, and we are modelling on the low end.”

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: xbc
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Should you buy AMZN? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Amazon (Amazon Stock… [Read More]

7 hours ago

These cannabis stocks will benefit most from reclassification

It happened. The move that everyone in the cannabis sector was hoping for came about swiftly on the last day… [Read More]

14 hours ago

Is AMD stock a buy? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Suji Desilva has maintained his "Buy" rating on Advanced Micro Devices… [Read More]

15 hours ago

Is Wolfspeed stock still a buy?

Ahead of the company's third quarter results, Roth MKM analyst Scott Irwin has maintained his "Buy" rating on Wolfspeed (Wolfspeed… [Read More]

15 hours ago

WELL Health inks five-year deal with Microsoft

It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]

2 days ago

Is Thomson Reuters stock a buy right now?

Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]

2 days ago